Moderna just exploded after what could be a huge breakthrough for mRNA cancer vaccines
Moderna and Merck announced that their personalized cancer vaccine intismeran, combined with Keytruda, significantly reduced the risk of melanoma returning or spreading in a Phase 3 trial. Moderna shares surged as much as 160% on the news. This is the first positive late-stage trial for an mRNA cancer vaccine, which is a pretty major validation of the technology beyond COVID.
The bigger question now is whether this becomes Moderna’s second act. If this platform starts working across multiple cancers, the company looks very different than a declining COVID-vaccine story.
Full Moderna data and Congressional activity:
https://app.walnutmarkets.com/ticker/MRNA
Do you think today’s move is justified by the Phase 3 result, or did a 100%+ move price in too much too quickly?